Search - tctmd.com

Displaying 1 - 20 of 29

Sort: Relevancy | Date

Presentation ESC 2025

DAPA ACT HF – TIMI 68: Dapagliflozin in Patients Hospitalized for Heart Failure

Presenter: David D. Berg

August 30, 2025

Presentation THT 2025

Use of AI for Improved HF Event Detection and Automated Drug Titration in Patients With and RPM Deice Planning for the Future: Perspective 1

Presenter: Harry Rowland

February 13, 2025

Presentation THT 2025

Use of AI for Improved HF Event Detection and Automated Drug Titration in Patients With and RPM Deice Planning for the Future: Perspective 2

Presenter: Kartik Sundareswaran

February 13, 2025

Presentation THT 2025

Impact of HF Pharmacological Therapy on the Durability of Favorable Response After LVAD Weaning: A VAD Wean Registry Analysis

Presenter: Stavros Drakos

February 12, 2025

Presentation THT 2025

Proactive Medical Management: GDMT & Diuretic Strategies Based on PA Pressure, Vital Signs, and Symptoms

Presenter: Michael Kiernan

February 12, 2025

Presentation THT 2025

Rationale for Mineralocorticoid Receptor Blockade with Finerenone in HF

Presenter: Carolyn Lam

February 12, 2025

Presentation THT 2025

The HF Physician's Approach: GDMT - Give the Darn Medicines a Try!

Presenter: Ryan Tedford

February 12, 2025

Presentation THT 2025

Impact of SGLT2 Inhibitors on Mortality and Cardiovascular Admissions in Heart Failure With Reduced Ejection Fraction (HFrEF)

Presenter: Jonathan Zawadzki

February 12, 2025

Presentation THT Abstracts 2025

Impact of HF Pharmacological Therapy on the Durability of Favorable Response After LVAD Weaning: A VAD Wean Registry Analysis

Presenter: Stavros Drakos

February 11, 2025

Presentation THT 2024

PH-HFpEF: Levosimendan

Presenter: Sanjiv J. Shah

March 06, 2024

Presentation THT Abstracts 2024

Disparities in Guideline Directed Medical Therapy (GDMT) Use and Dosing in Rural (versus Non-Rural) Veterans with Heart Failure with Reduced Ejection Fraction (HFrEF)

Presenter: Alexandra Steverson

March 05, 2024

Presentation THT 2024

A Case of Severe De Novo HF on Support for 14 days Without Evidence of Recovery

Presenter: Elena M. Donald

March 04, 2024

Presentation THT 2024

FDA-Approved But Less Frequently Used Device Therapies to Treat HFrEF: Challenges and Opportunities

Presenter: Michael R. Zile

March 04, 2024

Presentation Cardiovascular Interventions 2022

Do All Patients with New Onset HF Need Assessment for CAD?

Presenter: J. Thomas Heywood

October 28, 2022

Presentation TCT 2022

Moving Beyond Pharmacotherapy: The Transformative Role of Devices in HF Treatment

Presenter: William Abraham

September 16, 2022

Presentation TVT 2022

Design and Rationale of the CORCINCH-HF Pivotal Study

Presenter: Ulrich Jorde

June 09, 2022

Presentation TVT 2022

12-Month Outcomes for the AccuCinch System in HFrEF

Presenter: Nadira Hamid

June 09, 2022

Presentation TVT 2022

From Access to Anchors: The AccuCinch Ventricular Restoration System

Presenter: Azeem Latib

June 09, 2022

Presentation TVT 2022

Reverse Remodeling in Heart Failure

Presenter: Daniel Burkhoff

June 09, 2022

Presentation ARCH 2022

First Things First – Pharmacotherapy for HFrEF

Presenter: Georges Chahoud

April 23, 2022

Advertisement

DAPA ACT HF – TIMI 68: Dapagliflozin in Patients Hospitalized for Heart Failure

Use of AI for Improved HF Event Detection and Automated Drug Titration in Patients With and RPM Deice Planning for the Future: Perspective 1

Use of AI for Improved HF Event Detection and Automated Drug Titration in Patients With and RPM Deice Planning for the Future: Perspective 2

Impact of HF Pharmacological Therapy on the Durability of Favorable Response After LVAD Weaning: A VAD Wean Registry Analysis

Proactive Medical Management: GDMT & Diuretic Strategies Based on PA Pressure, Vital Signs, and Symptoms

Rationale for Mineralocorticoid Receptor Blockade with Finerenone in HF

The HF Physician's Approach: GDMT - Give the Darn Medicines a Try!

Impact of SGLT2 Inhibitors on Mortality and Cardiovascular Admissions in Heart Failure With Reduced Ejection Fraction (HFrEF)

Impact of HF Pharmacological Therapy on the Durability of Favorable Response After LVAD Weaning: A VAD Wean Registry Analysis

PH-HFpEF: Levosimendan

Disparities in Guideline Directed Medical Therapy (GDMT) Use and Dosing in Rural (versus Non-Rural) Veterans with Heart Failure with Reduced Ejection Fraction (HFrEF)

A Case of Severe De Novo HF on Support for 14 days Without Evidence of Recovery

FDA-Approved But Less Frequently Used Device Therapies to Treat HFrEF: Challenges and Opportunities

Do All Patients with New Onset HF Need Assessment for CAD?

Moving Beyond Pharmacotherapy: The Transformative Role of Devices in HF Treatment

Design and Rationale of the CORCINCH-HF Pivotal Study

12-Month Outcomes for the AccuCinch System in HFrEF

From Access to Anchors: The AccuCinch Ventricular Restoration System

Reverse Remodeling in Heart Failure

First Things First – Pharmacotherapy for HFrEF

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content